23andMe made a name for itself selling DNA test kits, but today it announced a radical new direction: The company will start mining its huge database of DNA sequences to create new drugs. The science of how they could do that is fascinating—but it raises a lot of futuristic ethical questions too.
University of Michigan's Risk Science Center offers a quick and handy explanation of the FDA's recent crackdown on personal genomics company 23andme. Some clean, even-keeled perspective to be had here. For more, see these musings from genomics expert (and member of 23andme's Scientific Advisory Board) Mike Eisen.